Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site

Acta Oncologica

Volumn 49, Issue 4, 2010, Pages 431-435

  Møller, Anne Kirstine Hundahl ^a   Pedersen, Karen Damgaard ^a   Abildgaard, Julie ^a   Petersen, Bodil Laub ^a   Daugaard, Gedske ^a  

^a University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BERLINOSTAT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GIMATECAN; METHOTREXATE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; SORAFENIB; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TRACT; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG EMBOLISM; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; ORGANOPLATINUM COMPOUNDS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 77951246611     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/02841861003649240     Document Type: Article

References (15)

1. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003;39:1990-2005.
2. Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol 2009;69:271-278
3. Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncol 2007;46:592-601.
4. Pentheroudakis G, Greco FA, Pavlidis N. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A ystematic literature review. Cancer Treat Rev 2009;35:221-227
5. Schuette K, Folprecht G, Kretzschmar A, Link H, Koehne CH, Gruenwald V, et al. Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary. Onkologie 2009;32:162-166
6. Culine S, Ychou M, Fabbro M, Romieu G, Cupissol D. 5-fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary site. Anticancer Res 2001;21:1455-1457
7. Hainsworth JD, Burris HA, III, Calvert SW, Willcutt NT, Scullin DC, Jr., Bramham J, et al. Gemcitabine in the secondline therapy of patients with carcinoma of unknown primary site: A phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest 2001;19:335-339
8. Hainsworth JD, Spigel DR, Raefsky EL, Kuzur ME, Yost K, Kommor M, et al. Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: A Minnie Pearl Cancer Research Network Phase II trial. Cancer 2005;104:1992-1997
9. Pouessel D, Culine S, Becht C, Romieu G, Fabbro M, Ychou M, et al. Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site. Anticancer Res 2003;23:2801-2804
10. Briasoulis E, Pavlidis N, Felip E. Cancers of unknown primary site: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl 4):154-155
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216 (Pubitemid 30099779)
12. Møller A, Pedersen K, Gothelf A, Daugaard G. Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study. Acta Oncol 2010;49:423-430
13. Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002;20:4679-4683
14. Ponce LJ, Segura HA, Diaz BR, Gimenez OA, Aparisi AF, Fleitas KT, et al. Carcinoma of unknown primary site: Development in a single institution of a prognostic model based on clinical and serum variables. Clin Transl Oncol 2007;9:452-458
15. Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: The Minnie Pearl Cancer Research Network. J Clin Oncol 2007;25:1747-1752